Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia

Authors:

Abstract
No abstract available
Funding Information
  • National Cancer Institute
  • SymBio Pharmaceuticals Limited
  • Teva Pharmaceutical Industries
  • Amgen
  • Celgene
  • Bristol-Myers Squibb
  • University of Texas MD Anderson Cancer Center (CA016672)
  • Pfizer
  • Astellas Pharma Global Development
  • Sunesis
  • Novartis
  • Merck

This publication has 38 references indexed in Scilit: